1. Home
  2. UK vs ENTO Comparison

UK vs ENTO Comparison

Compare UK & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UK
  • ENTO
  • Stock Information
  • Founded
  • UK 2015
  • ENTO 2014
  • Country
  • UK China
  • ENTO United States
  • Employees
  • UK N/A
  • ENTO N/A
  • Industry
  • UK Business Services
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • UK Consumer Discretionary
  • ENTO Health Care
  • Exchange
  • UK Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • UK 2.2M
  • ENTO 1.9M
  • IPO Year
  • UK N/A
  • ENTO 2016
  • Fundamental
  • Price
  • UK $1.02
  • ENTO $0.47
  • Analyst Decision
  • UK
  • ENTO
  • Analyst Count
  • UK 0
  • ENTO 0
  • Target Price
  • UK N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • UK 14.5K
  • ENTO 1.6M
  • Earning Date
  • UK 07-29-2025
  • ENTO 05-15-2025
  • Dividend Yield
  • UK N/A
  • ENTO N/A
  • EPS Growth
  • UK N/A
  • ENTO N/A
  • EPS
  • UK N/A
  • ENTO N/A
  • Revenue
  • UK $23,924,045.00
  • ENTO N/A
  • Revenue This Year
  • UK N/A
  • ENTO N/A
  • Revenue Next Year
  • UK N/A
  • ENTO N/A
  • P/E Ratio
  • UK N/A
  • ENTO N/A
  • Revenue Growth
  • UK N/A
  • ENTO N/A
  • 52 Week Low
  • UK $0.98
  • ENTO $0.19
  • 52 Week High
  • UK $2.26
  • ENTO $1.11
  • Technical
  • Relative Strength Index (RSI)
  • UK 47.10
  • ENTO 51.42
  • Support Level
  • UK $1.02
  • ENTO $0.44
  • Resistance Level
  • UK $1.11
  • ENTO $0.51
  • Average True Range (ATR)
  • UK 0.04
  • ENTO 0.05
  • MACD
  • UK 0.00
  • ENTO 0.00
  • Stochastic Oscillator
  • UK 30.77
  • ENTO 53.27

About UK Ucommune International Ltd

Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. Company provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has three operating segments: Workspace membership, Marketing and branding services, and Other services. Marketing and branding services generate the majority of the company's revenue.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: